diabetestalk.net

Clinical Investigation Diabetes

Yale Center For Clinical Investigation > Diabetes Research Center | Internal Medicine | Yale School Of Medicine

Yale Center For Clinical Investigation > Diabetes Research Center | Internal Medicine | Yale School Of Medicine

Blood and other sample processing facility, Freezers and refrigerators for blood and tissue specimens to be stored in a safe and secure location, Storage space, locked supply and medication room, Space for receptionists (who will document subject visits and provide scheduling services) and administrative assistants, Small conference area. The importance of the new Outpatient Center extends beyond simple enhancement of space for clinical studies. Having a central location for outpatient studies will facilitate cost-effective utilization of research staff (e.g., nurse coordinators) that may be engaged in studies with more than one investigator, as well as oversight of ongoing studies. Use of YCCI research staff will free investigators of many of the burdens of administrating the day-to-day management and enhance the quality of supervision and oversight of research staff. Integration of activities of the YCCI Outpatient Clinical and Translational Research Center and the Operations Center will be facilitated by locating both important components of our program in the same location. It should also be noted that the site at 2 Church Street South was selected because it is in close proximity to the academic offices of research faculty in the Yale School of Nursing and EPH, as well as the School of Medicine. The outpatient center will also serve as a training and certification site for new study coordinators and research assistants. This resource originally served as the core laboratory of the GCRC. Because a major strength of the GCRC was in patient-based diabetes-related research, the primary orientation of this laboratory has been substrate, hormone and cytokine analyses, and thus directly relevant to DERC research programs. As a result, this facility's technical staff and Continue reading >>

Helping To Steady The Balancing Act Of Diabetes

Helping To Steady The Balancing Act Of Diabetes

Helping to Steady the Balancing Act of Diabetes The five teenagers who went rock climbing at City Climb in New Haven, Connecticut were typical high school students who lead busy, active lives. What sets them apart is that they were taking part in a pioneering clinical trial to test a system for treating their type 1 diabetes, which can be complicated to manage. Everything in my life basically revolves around it, said Jacob Conte, 15. The standard treatment for children and teenagers with type 1 diabetes is either multiple daily insulin injections or the use of an insulin pump. All of the teens in the study use the pump, first tested at Yale in 1979, to deliver the insulin that helps control their blood sugar. While the pump has advanced diabetes treatment tremendously, it must be operated manually to deliver the correct doses of insulin. Yale doctors have worked with industry partners to develop what many refer to as an artificial pancreas, an insulin pump that works with a continuous glucose sensor to automatically adjust insulin delivery in response to the bodys demand. This closed-loop system, in which the sensor controls the pump on a minute-by-minute basis, would be a major advance for patients with diabetes. The ability of the system to self adjust automatically in the background while patients go about their daily lives would really be transformative in the lives of people with diabetes, said Stuart Weinzimer, MD, who led the study. During the clinical trial, the teens spent four days round-the-clock with a team of Yale doctors and nurses who monitored their blood sugar levels while they took part in activities that included hiking, playing laser tag, and climbing a rock wall. The idea was to challenge the system to keep up with kids acting like kids, said Dr. W Continue reading >>

Clinical Research And Epidemiology In Diabetes And Endocrinology

Clinical Research And Epidemiology In Diabetes And Endocrinology

Johns Hopkins Bloomberg School of Public Health Clinical Research and Epidemiology in Diabetes and Endocrinology Hugh P. McCormick Family Professor of Endocrinology and Metabolism Executive Vice-Chair, Department of Medicine Director, Inpatient Diabetes Management Service Division of Endocrinology, Diabetesand Metabolism Diabetes mellitus has reached epidemic proportions in the US and abroad. Other endocrinologic diseases, like hypothyroidism and osteoporosis are also extraordinarily common. Patient- and population-oriented researchers with expertise in these conditions are urgently required. With this need in mind, in 2002, we established a training program at Johns Hopkins devoted to clinical and epidemiologic research in diabetes and endocrinology and funded by the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK). Ten years later, it remains the only one of its kind in the US. The training program accepts three pre-doctoral students and three post-doctoral fellows per year and leads them to the MHS or PhD in clinical epidemiology or clinical investigation.Thus far, we have successfully trained 22 young scholars (9 pre-docs and 13 post-docs) who have produced over 65 peer-reviewed scientific papers and who hold research positions across the country. To recruit a diverse group of top-notch young trainees in endocrinology (post-docs) and epidemiology (pre-docs) from a national pool of talent attracted to Johns Hopkins. To enroll them in rigorous, thesis-bearing Masters and PhD programs in Epidemiology and Clinical Investigation in the Johns Hopkins Bloomberg School of Public Health. To expose them to a strong team-oriented, multi-disciplinary clinical and epidemiologic research culture in the Welch Centerthe premier educational home for clinical r Continue reading >>

Nellis Air Force Base

Nellis Air Force Base

The primary mission of the Nellis Air Force Base Clinical Investigation Program (CIP) is to support Graduate Medical education research. We also have interests in developing and testing alterative treatment for pain and utilizing nutraceuticals to treat and mitigate disease and other conditions. The Mike O'Callaghan Military Medical Center at Nellis Air Force base was selected as a new CIP in FY12 and has participated in 69 investigations since its inception. We hold 2 active Investigational New Drug Applications, 1 Compassionate Use Protocol, and 1 Humanitarian Use Device (HUD) through the Food and Drug Administration. Nellis AFB is the first CIP within the Air Combat Command. The Nellis Family Medicine Residency (FMR) was awarded the Outstanding Achievement in Scholarly Activity award from the Uniformed Services Academy of Family Physicians in 2014, 2015, 2016, and 2017. The award is given for the number of publications and presentations at National, International, and Regional Meetings for the previous academic year. In 2014, the CIP was awarded the Training and Education award by the Association of Military Surgeons of the United States (AMSUS). We are participating in the Military Primary Care Research Network, which is a network of Family Medicine research sites coordinated by Uniformed Services University of the Health Sciences. We have several agreements with industry sponsors, and are actively seeking out new funding opportunities. Title: Auricular Acupuncture: A novel application in ureteral stent pain. Purpose: The purpose of this study is to compare standard postoperative therapy plus battlefield auricular acupuncture (BFA) versus standard postoperative therapy alone in decreasing pain, urinary urgency, frequency, dysuria, reduced pain medication use, and t Continue reading >>

Pre-clinical Investigation Of Diabetes Mellitus As A Risk Factor For Schizophrenia.

Pre-clinical Investigation Of Diabetes Mellitus As A Risk Factor For Schizophrenia.

Behav Brain Res. 2017 May 30;326:154-164. doi: 10.1016/j.bbr.2017.02.043. Epub 2017 Mar 8. Pre-clinical investigation of Diabetes Mellitus as a risk factor for schizophrenia. Laboratrio de Neurocincias and Instituto Nacional de Cincia e Tecnologia Translacional em Medicina (INCT-TM), Programa de Ps-Graduao em Cincias da Sade, Unidade Acadmica de Cincias da Sade, Universidade do Extremo Sul Catarinense, 88806-000, Cricima, SC, Brazil. Laboratrio de Biologia Celular e Molecular, Programa de Ps-graduao em Cincias da Sade, Unidade Acadmica de Cincias da Sade, Universidade do Extremo Sul Catarinense, Cricima, SC, Brazil. Laboratrio de Neurocincias and Instituto Nacional de Cincia e Tecnologia Translacional em Medicina (INCT-TM), Programa de Ps-Graduao em Cincias da Sade, Unidade Acadmica de Cincias da Sade, Universidade do Extremo Sul Catarinense, 88806-000, Cricima, SC, Brazil; Center for Experimental Models in Psychiatry, Department of Psychiatry and Behavioral Sciences, Medical School, University of Texas Health Science Center at Houston, Houston, TX 77054, USA. Laboratrio de Neurocincias and Instituto Nacional de Cincia e Tecnologia Translacional em Medicina (INCT-TM), Programa de Ps-Graduao em Cincias da Sade, Unidade Acadmica de Cincias da Sade, Universidade do Extremo Sul Catarinense, 88806-000, Cricima, SC, Brazil. Electronic address: [email protected] This study investigated the behavioral and biochemical parameters of DM1 as a risk factor in an animal model of schizophrenia (SZ). All groups: 1 Control (saline+saline); 2 Alloxan (alloxan+saline); 3 Ketamine (saline+ketamine); 4 (Alloxan+Ketamine) were fasted for a period of 18h before the subsequent induction of DM via a single intraperitoneal (i.p) injection of alloxan (150mg/kg). From the 4th to the 10th days, the a Continue reading >>

Programs In Clinical Investigation

Programs In Clinical Investigation

Boston Universitys programs inClinical Investigation aim to meet the needs of health professionals engaged in the full-spectrum of patient-oriented research. We offer both masters degree and certificate programs to individuals seeking careers in clinical research in industry or academic settings. Clinical Investigation program offerings: Dual Degree in Medicine and Clinical Investigation About the MS in Clinical Investigation Program (MSCI) Located in BostonsSouth End at the Boston UniversitySchool of Medicine, theMaster of Science inClinicalInvestigation Program (MSCI) has been in existence since 2001. As an entity of BUSM, students are provided with opportunities and are exposed to resources that are part of the School of Medicine , the School of Public Health , the Goldman School of Dental Medicine , Boston Medical Center , two VA Administrations, and BioSquare. All of this offers students endless opportunities for personal, academic and professional development. The MSCI program teaches students the scientific fundamentals of human research. Courses in our curriculum provide an in-depth look at all of the key elements in clinical investigation, including: trial design, trial management, biostatistics, ethical issues, and clinical research regulations. Other courses cover how basic science discoveries translate into clinical investigation and new therapies. The total course requirement is 32 credit hours: 18 hours are required curriculum; 14 hours are elective courses. Students will also complete a research practicum; a hands-on involvement in a clinical research project under a scientific mentor. The final requirement for the degree is to conduct clinical research, write, and present a research thesis. The MSCI program is designed for anyone interested in a career Continue reading >>

Critical Link Between Obesity And Diabetes Has Been Identified

Critical Link Between Obesity And Diabetes Has Been Identified

Critical link between obesity and diabetes has been identified November 28, 2017, UT Southwestern Medical Center UTSouthwestern researchers have identified a major mechanism by which obesity causes type 2 diabetes, which is a common complication of being overweight that afflicts more than 30 million Americans and over 400 million people worldwide. Researchers found that in obesity, insulin released into the blood by the pancreas is unable to pass through the cells that form the inner lining of blood vessels . As a result, insulin is not delivered to the muscles, where it usually stimulates most of the body's glucose to be metabolized. Blood glucose levels rise, leading to diabetes and its related cardiovascular, kidney and vision problems, said Dr. Philip Shaul, Director of the Center for Pulmonary and Vascular Biology in the Department of Pediatrics at UTSouthwestern. "It was totally unpredicted that a major problem in obesity is the delivery of circulating insulin to your muscle. It was even more surprising that this problem involves immunoglobulins, which are the proteins that make up circulating antibodies," said Dr. Chieko Mineo, Associate Professor of Pediatrics, who is a co-senior author on the report with Dr. Shaul. The researchers found that obese mice have an unexpected chemical change in their immunoglobulins. "The abnormal immunoglobulins then act on cells lining blood vessels to inhibit an enzyme needed to transfer insulin from the bloodstream into the muscle," said Dr. Shaul, who holds the Associates First Capital Corporation Distinguished Chair in Pediatrics. "Type 2 diabetes patients have the same chemical change, and if we give a mouse immunoglobulins from a type 2 diabetic individual, the mouse becomes diabetic." The findings reported in The Journal o Continue reading >>

The Clinical Investigation Of<i> Securigera Securidaca</i> (l.) Degen [amp] Doerfler Seeds In Treatment Of Type Ii Diabetic Patients; A Randomized, Double - Blind, Placebo - Controlled Study.

The Clinical Investigation Of Securigera Securidaca (l.) Degen [amp] Doerfler Seeds In Treatment Of Type Ii Diabetic Patients; A Randomized, Double - Blind, Placebo - Controlled Study.

The Clinical Investigation Of Securigera Securidaca (l.) Degen [amp] Doerfler Seeds In Treatment Of Type Ii Diabetic Patients; A Randomized, Double - Blind, Placebo - Controlled Study. Backgrounds and Aims: Secur Backgrounds and Aims: Securigera securidaca (L.) seeds is used by traditional herbalists for the treatment of diabetes in several parts of Iran. Clinical investigation of its efficacy and its toxicity in diabetic patients is of importance. Methods: A 2 - month randomized double blind clinical trail was conducted in 70 type II diabetic patients in two well - matched groups. One group (n=35) received 500 mg Securigera securidaca (L.) seeds capsule 3 times a day plus standard therapy, while the control group (n=35) received placebo plus standard therapy. The patients were visited monthly and glycosylated hemoglobin (HbA1c), fasting blood glucose, total cholesterol, LDL and HDL triglyceride, SGOT, SGPT, ALK, BUN, serum ceratinin levels were determined at the beginning and the end of the study after two months. Results: There was no significant change in HbA1c and fasting blood glucose level in Securigera securidaca (L.) seeds treated patients after two month as compared to beginning of the treatment and also as compared to placebo group. Serum lipid level was also not change significantly. The liver enzyme level and ceratinin level in blood was not changed significantly in Securigera securidaca (L.) seeds treated patients. No side effect was observed in all of patients in both groups. Conclusion: The results showed that the Securigera securidaca (L.) seeds treatment with known antidiabetic property in traditional herbal therapy has no beneficial effect on improving glycemic profile in type II diabetic patients. The use of this herbal medicine in the dose of 1500 m Continue reading >>

Pre-clinical Investigation Of Diabetes Mellitus As A Risk Factor For Schizophrenia

Pre-clinical Investigation Of Diabetes Mellitus As A Risk Factor For Schizophrenia

Universidade do Extremo Sul Catarinense (UNESC) This study investigated the behavioral and biochemical parameters of DM1 as a risk factor in an animal model of schizophrenia (SZ). All groups: 1 Control (saline + saline); 2 Alloxan (alloxan + saline); 3 Ketamine (saline + ketamine); 4 (Alloxan + Ketamine) were fasted for a period of 18 hours before the subsequent induction of DM via a single intraperitoneal (i.p) injection of alloxan (150 mg/kg). From the 4th to the 10th days, the animals were injected i.p with ketamine (25 mg/kg) or saline, once a day, to induce a model of SZ and 30 minutes after the last administration were subjected to behavioral testing. After, the animals were decapitated and the brain structures were removed. Ketamine induced hyperactivity and in the social interaction, ketamine, alloxan and the association of alloxan + ketamine increased the latency and decreased the number of contacts between animals. The animals from the ketamine, alloxan and alloxan + ketamine groups showed a prepulse startle reflex (PPI) deficit at the three intensities (65, 70 and 75 dB). Ketamine was shown to be capable of increasing the activity of acetylcholinesterase (AChE) in the brain structures. Combination of alloxan + ketamine seems to have an exacerbated effect within the cholinergic system. For lipid peroxidation and protein carbonyls, alloxan + ketamine appear to have intensified lipid and protein damage in the three structures. Ketamine and the combination of ketamine + alloxan induced DNA damage in both frequency and damage index. This research found a relationship between DM1 and SZ. Do you want to read the rest of this article? Continue reading >>

Common Blood Pressure Drug May Prevent Type 1 Diabetes

Common Blood Pressure Drug May Prevent Type 1 Diabetes

Common blood pressure drug may prevent type 1 diabetes Researchers from Colorado and Florida have found that a drug commonly used to control blood pressure could have another use: preventing and treating type 1 diabetes. Researchers have identified a blood pressure drug that could help to prevent type 1 diabetes. The new research co-authored by Dr. Aaron Michels, an associate professor of medicine at the University of Colorado Anschutz Medical Campus in Aurora will be published in The Journal of Clinical Investigation. Type 1 diabetes is a condition in which the beta cells of the pancreas are unable to produce enough insulin , which is the hormone that regulates blood sugar levels. This is believed to be down to an autoimmune process, wherein the immune cells mistakingly attack and destroy beta cells. Around 5 percent of all diabetes cases are type 1. It is most commonly diagnosed during childhood, adolescence, or young adulthood, but it can develop at any age. While the exact causes of type 1 diabetes remain a mystery, Dr. Michels and team note that around 60 percent of those who are at risk of the condition possess a molecule called DQ8 which previous research has linked to the onset of type 1 diabetes. With this in mind, the researchers speculate that blocking the DQ8 molecule could be one way of preventing type 1 diabetes. In their latest study, they identified an existing drug that could do just that. The researchers came to their findings by using a "supercomputer" to analyze every small molecule drug that had been approved by the Food and Drug Administration (FDA). Specifically, they investigated whether any of these medications could target and inhibit the DQ8 molecule. They found one that hit the mark: a drug called methyldopa , which is most often prescribed Continue reading >>

Clinical Investigation Of Galnobax For The Treatment Of Diabetic Foot Ulcers

Clinical Investigation Of Galnobax For The Treatment Of Diabetic Foot Ulcers

You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Clinical Investigation of Galnobax for the Treatment of Diabetic Foot Ulcers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ClinicalTrials.gov Identifier: NCT01113515 Verified April 2015 by Novalead Pharma Private Limited. Recruitment status was: Active, not recruiting Information provided by (Responsible Party): Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information The purpose of this study is to determine safety and efficacy of a new gel formulation of Esmolol hydrochloride (Galnobax) for the treatment of Diabetic Foot Ulcer (DFU). The study will compare number and types of adverse events occured, rates of wound closure and percentage of wounds closed in Galnobax treated groups versus placebo group. Drug: Esmolol hydrochloride Drug: Placebo gel This is an interventional, placebo-controlled, randomized, double-blinded, dose comparison, phase I/II study of Galnobax in subjects with diabetic foot ulcers. Additionally the effect of dosage and frequency of application will also be studied . The total trial duration per subject is 25 weeks which comprises of 1 week for screening, 12 weeks of treatment and 12 weeks of follow-up. Triple (Participant, Care Provider, Investigator) An Interventional, Placebo-Controlled, Randomized, Double-blinded Dose Comparison, Phase I/II Study to Determine the Safety and Efficacy of a New Gel Formulation of Esmolol Hydrochloride (Galnobax) for the Treatment of Diabetic Foot U Continue reading >>

Doce Researchers Published In Journal Of Clinical Investigation

Doce Researchers Published In Journal Of Clinical Investigation

Diabetes and Obesity Center of Excellence DOCE Researchers Published in Journal of Clinical Investigation DOCE Director Michael W. Schwartz, MD (MTE) is senior author of a paper published in theJournal of Clinical Investigationthat presents the first evidence of structural change in the brain in both rodents and humans associated with diet-induced obesity. DOCE researcher Dr. Josh Thaler, MD, PhD, (MTE), is the first author on the paper entitled Obesity Is Associated with Hypothalamic Injury in Rodents and Humans which was published in the January 3rd issue. Other DOCE investigators co-authoring the paper are Stephan J. Guyenet, PhD (MTE), Gregory J. Morton, PhD (MTE), and Brent E. Wisse, MD (MTE). Along with colleagues from the UW Departments of Medicine and Radiology as well as Yale University and the University of Cincinnati, the group studied the effect of high-fat diet consumption on the brain health of mice and rats. They found evidence of very early and lasting injury to a specific part of the hypothalamus, a brain area critically involved in the regulation of body weight. Similarly, analysis of brain MRIs from a group of healthy people with a wide range of body weights revealed signs of damage to the hypothalamus in the obese subjects. Together, these findings provide a potential explanation for the difficulty in achieving and maintaining weight loss once obesity has become established. The paper has attracted wide media attention nationally and internationally. Dr. Schwartz was heard on January 3rd on KUOW , and Dr. Thaler on KING5 television December 30, among many other reports. Continue reading >>

Clinical Trials On Diabetes Mellitus

Clinical Trials On Diabetes Mellitus

Open Access is an initiative that aims to make scientific research freely available to all. To date our community has made over 100 million downloads. Its based on principles of collaboration, unobstructed discovery, and, most importantly, scientific progression. As PhD students, we found it difficult to access the research we needed, so we decided to create a new Open Access publisher that levels the playing field for scientists across the world. How? By making research easy to access, and puts the academic needs of the researchers before the business interests of publishers. We are a community of more than 103,000 authors and editors from 3,291 institutions spanning 160 countries, including Nobel Prize winners and some of the worlds most-cited researchers. Publishing on IntechOpen allows authors to earn citations and find new collaborators, meaning more people see your work not only from your own field of study, but from other related fields too. Blas Gil Extremera, Pilar Jimnez Lpez, Alberto Jess Guarnido Ramrez, Elizabet Garca Pealver, Maria Luz Abarca Martnez and Isabel Mrida Fernndez (April 1st 2015). Clinical Trials on Diabetes Mellitus, Treatment of Type 2 Diabetes Colleen Croniger, IntechOpen, DOI: 10.5772/59130. Available from: Blas Gil Extremera, Pilar Jimnez Lpez, Alberto Jess GuarnidoRamrez, Elizabet Garca Pealver, Maria Luz Abarca Martnez andIsabel Mrida Fernndez (April 1st 2015). Clinical Trials on Diabetes Mellitus, Treatment of Type 2 Diabetes Colleen Croniger, IntechOpen, DOI: 10.5772/59130. Available from: Embed this chapter on your site Copy to clipboard Embed this code snippet in the HTML of your website to show this chapter Over 21,000 IntechOpen readers like this topic Help us write another book on this subject and reach those readers Continue reading >>

Pre-clinical Investigation Of Diabetes Mellitus As A Risk Factor For Schizophrenia

Pre-clinical Investigation Of Diabetes Mellitus As A Risk Factor For Schizophrenia

Pre-clinical investigation of Diabetes Mellitus as a risk factor for schizophrenia Type 1 Diabetes Mellitus can be considered a predisposing factor for schizophrenia. Association alloxan+ketamine induced deficit in social interaction between animals. Alloxan+ketamine group showed a PPI deficit at all three intensities evaluated. Alloxan+ketamine seems to have an exacerbated effect within the cholinergic system. Combination alloxan+ketamine intensified oxidative damage in the brain structures. This study investigated the behavioral and biochemical parameters of DM1 as a risk factor in an animal model of schizophrenia (SZ). All groups: 1 Control (saline+saline); 2 Alloxan (alloxan+saline); 3 Ketamine (saline+ketamine); 4 (Alloxan+Ketamine) were fasted for a period of 18h before the subsequent induction of DM via a single intraperitoneal (i.p) injection of alloxan (150mg/kg). From the 4th to the 10th days, the animals were injected i.p with ketamine (25mg/kg) or saline, once a day, to induce a model of SZ and 30min after the last administration were subjected to behavioral testing. After, the animals were decapitated and the brain structures were removed. Ketamine induced hyperactivity and in the social interaction, ketamine, alloxan and the association of alloxan+ketamine increased the latency and decreased the number of contacts between animals. The animals from the ketamine, alloxan and alloxan+ketamine groups showed a prepulse startle reflex (PPI) deficit at the three intensities (65, 70 and 75dB). Ketamine was shown to be capable of increasing the activity of acetylcholinesterase (AChE) in the brain structures. Combination of alloxan+ketamine seems to have an exacerbated effect within the cholinergic system. For lipid peroxidation and protein carbonyls, alloxan+ketam Continue reading >>

Diabetic Remission Clinic

Diabetic Remission Clinic

Leading researchers at the Royal Veterinary College are busy unravelling the riddle for the best treatment of diabetes mellitus in cats. Dr. Stijn Niessen and his team run the Diabetic Remission Clinic in the Queen Mother Hospital for Animals in Hertfordshire, investigating the optimum methods to achieve good control, and ultimately diabetic remission, in diabetic pets. Currently, the Clinic provides dedicated care for diabetic cats while giving owners and vets the satisfaction of contributing to veterinary research and benefit of specialist advice on diabetic management. . A proportion of diabetic cats can enter a state of diabetic remission and no longer require insulin treatment. However, these cats can still have reduced pancreatic β-cell function and mass, and approximately 30% of them will experience a relapse of their diabetes and require insulin therapy to be reinstated. Drugs that can promote insulin secretion, and stimulate β-cell proliferation and survival might be beneficial in helping diabetic cats achieve remission, and in preventing relapse of diabetes in cats that are already in remission. With our new clinical trial, we aim to investigate the benefit of one such drug in newly diagnosed diabetic cats (treated with insulin for no more than 6 months) as well as in cats that have recently entered diabetic remission (last insulin injection no longer than 4 months ago). Diabetic cats, and cats in remission, will be eligible for a 6 months and a 1-year trial, respectively, and will benefit from initial underlying disease assessment, monthly re-examinations at our dedicated diabetic remission clinic, free treatment with the trial drug, as well as a supply of insulin (in diabetic cats) and a year’s supply of high-protein, low-carbohydrate diet – all at no Continue reading >>

More in diabetes